Related Experiment Videos
[Therapeutic principles for chronic inflammatory bowel disease]
1Medicinsk-gastroenterologisk afdeling C, Amtssygehuset i Herlev.
Ugeskrift for Laeger
|October 6, 2001
Summary
The incidence of Crohn's disease is rising, while ulcerative colitis remains stable. Treatment focuses on remission and prevention using medications like 5-aminosalicylic acid and newer agents, with surgery as a last resort for severe inflammatory bowel disease.
Area of Science:
- Gastroenterology and Immunology
- Inflammatory Bowel Disease (IBD) Research
Context:
- Rising incidence of Crohn's disease over three decades.
- Stable incidence of ulcerative colitis.
- Inclusion of collagenous colitis and lymphocytic colitis under chronic inflammatory bowel disease.
Purpose:
- To review current understanding and treatment principles for inflammatory bowel diseases.
- To highlight advancements in pharmaceutical and surgical interventions for IBD.
Summary:
- IBD treatment aims to induce and maintain remission.
- Pharmacological options include 5-aminosalicylic acid, glucocorticoids, immunosuppressants (e.g., azathioprine), and novel immunomodulators.
- Infliximab (a TNF-alpha antibody) is used for severe Crohn's disease.
- Surgery is curative for ulcerative colitis but involves ileostomy or ileal pouch procedures.
- Crohn's disease surgery is less curative and emphasizes bowel preservation.
Impact:
- Provides an overview of IBD management strategies.
- Informs about the evolving landscape of IBD treatment, including new therapies.
- Discusses surgical outcomes and considerations for both ulcerative colitis and Crohn's disease.